Clinical Validation of Continuous Glucose Monitoring in Glycemic Management of Critically Ill Sepsis Patients
Clinical Validation of Continuous Glucose Monitoring in Glycemic Management of Critically Ill Sepsis Patients: A Prospective Randomized Clinical Study
調査の概要
状態
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Zhejiang
-
Taizhou、Zhejiang、中国、318000
- Taizhou municipal hospital
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Age ≥ 18 years.
- Confirmed infection accompanied by an increase in Sequential Organ Failure Assessment (SOFA) score of ≥ 2 points.
- Written informed consent provided by the patient or legally authorized representative.
Exclusion Criteria:
- Discharge against medical advice or transfer to another facility before study completion, leading to incomplete data.
- Non-cooperation with study procedures.
- Contraindications to the application of the flash glucose monitoring sensor (e.g., severe skin disease at insertion site, known allergy to sensor components).
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
CGM Group (Intervention)
|
Intervention Group (CGM Group): Patients receive continuous glucose monitoring using the factory-calibrated FreeStyle Libre II system (Abbott Diabetes Care Ltd, UK). A sensor is inserted subcutaneously on the posterior aspect of the upper arm and measures interstitial glucose levels in real time. Glucose values and trend data are displayed on a reader device and are accessible to the clinical team remotely. In addition to CGM, all patients in this group also undergo standard conventional monitoring (fingertip capillary glucose, arterial blood gas, and venous blood glucose measurements) per routine ICU practice. Insulin therapy is initiated when blood glucose reaches ≥10 mmol/L. |
|
Control Group (Active Comparator)
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Accuracy of CGM (MARD < 15%, ISO compliance, and DTS error grid Zones A+B)
時間枠:Throughout the 1-2 week ICU stay
|
Throughout the 1-2 week ICU stay
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Protocol Adherence Rate
時間枠:Throughout the 1-2 week ICU stay
|
Percentage of completed glucose measurements relative to the total prescribed tests per protocol.Unit of Measure: % (percentage)
|
Throughout the 1-2 week ICU stay
|
|
Target Glucose Achievement Rate
時間枠:Throughout the 1- to 2-week ICU stay.
|
Proportion of glucose readings falling within the target range of 7.8-10.0
mmol/L.Unit of Measure: % (percentage)
|
Throughout the 1- to 2-week ICU stay.
|
|
Hypoglycemia Detection Rate
時間枠:Throughout the 1- to 2-week ICU stay.
|
Incidence of hypoglycemic events (glucose ≤ 3.9 mmol/L) detected, calculated as number of events divided by total number of measurements × 100%.Unit of Measure: % (percentage)
|
Throughout the 1- to 2-week ICU stay.
|
|
Hyperglycemia Detection Rate
時間枠:hroughout the 1- to 2-week ICU stay.
|
Incidence of hyperglycemic events (glucose ≥ 11.1 mmol/L) detected, calculated as number of events divided by total number of measurements × 100%.Unit of Measure: % (percentage)
|
hroughout the 1- to 2-week ICU stay.
|
|
Nursing Time per Measurement
時間枠:Throughout the 1- to 2-week ICU stay.
|
Average time required for nursing staff to complete a single glucose measurement (from preparation to recording result).seconds
(or minutes, as appropriate; your study reports seconds)
|
Throughout the 1- to 2-week ICU stay.
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- KTSB-WST-2022-014
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。